

Appendix 1. Comparison of Total Number of Amenorrhea/Spotting Days and Bleeding Days During the 30-Day Periods, Excluding Patients Who Were Lost To Follow-up Before Completion of These Periods, Using Wilcoxon's Rank-Sum Test

Bleeding Outcome	Days	Tamoxifen		Placebo		Rank-sum p-value
		n	Median (Range)	n	Median (Range)	
Amenorrhea/Spotting	1-30	53	26 (5-30)	51	20 (1-30)	< 0.001
	31-60	49	24 (0-30)	47	24 (0-30)	0.953
	61-90	46	27 (0-30)	42	23.5 (10-30)	0.008
	91-120	41	24 (2-30)	42	25 (8-30)	0.316
	121-150	39	25 (1-30)	42	27 (0-30)	0.357
	151-180	39	24 (0-30)	40	25 (0-30)	0.894
Bleeding	1-30	53	4 (0-25)	51	10 (0-29)	< 0.001
	31-60	49	6 (0-30)	47	6 (0-30)	0.968
	61-90	46	3 (0-30)	42	6.5 (0-20)	0.007
	91-120	41	6 (0-28)	42	5 (0-22)	0.316
	121-150	39	5 (0-29)	42	3 (0-30)	0.377
	151-180	39	3 (0-20)	40	4 (0-30)	0.236

Edelman AB, Kaneshiro B, Simmons KB, Hauschildt JL, Bond K, Boniface ER, et al. Treatment of unfavorable bleeding patterns in contraceptive implant users: a randomized controlled trial. *Obstet Gynecol* 2020;135. The authors provided this information as a supplement to their article.